Amgen Inc. (0R0T.IL)
IOB - IOB Delayed price. Currency in USD
Add to watchlist
At close: 07:12PM BST
| Previous close | 276.75 |
| Open | 317.41 |
| Bid | 290.50 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 310.81 - 321.96 |
| 52-week range | 211.96 - 329.12 |
| Volume | |
| Avg. volume | 35,816 |
| Market cap | 167.564B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 20.60 |
| EPS (TTM) | 14.84 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | 8.52 (3.04%) |
| Ex-dividend date | 17 Aug 2023 |
| 1y target est | N/A |
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Barrons.comThese Stocks Moved the Most Today: Apple, Amgen, Expedia, Coinbase, Cloudflare, Fortinet, Live Nation, and More
Apple reports better-than-estimated earnings and expands its buyback program by $110 billion, Amgen ‘very encouraged’ by preliminary data from a trial of a weight-loss drug, and Expedia reduces its sales outlook for the year.
Investor's Business DailyAmgen Is 'Very Encouraged' With Its Obesity Drug. But Can It Take On Novo, Lilly Duopoly?
Amgen stock neared its record high Friday after the company said it's "very encouraged" with midstage test results for its obesity treatment.
© 2024 Yahoo. All rights reserved.